Ball Titus B. 4

What Happened
Titus B. Ball, Principal Accounting Officer of BeOne Medicines (ONC), received a grant of 31,213 restricted share units (RSUs) on June 11, 2026 (acquired at $0.00). On the same date he sold 49 ADS at $256.39 and 120 ADS at $257.53 in open-market/private sale transactions, generating combined proceeds of about $43,468. The sales were effected to satisfy tax withholding obligations related to the vesting of a previously granted RSU award.

Key Details

• Transaction date: June 11, 2026.
• Award: 31,213 RSUs granted (reported as acquisition at $0.00). Vesting: 1/4th vests on each anniversary (see footnote F1).
• Sales: 49 ADS @ $256.39 (≈ $12,564) and 120 ADS @ $257.53 (≈ $30,904); total ≈ $43,468. Sales were for tax withholding (footnote F3).
• ADS conversion: Each American Depositary Share (ADS) represents 13 ordinary shares (footnote F2). The 169 ADS sold equal 1,697 ordinary shares? Correction: 169 ADS × 13 = 2,197 ordinary shares.
• Shares owned after the reported transactions: Not specified in the filing.
• Filing timeliness: Report filed June 15, 2026 for a June 11 transaction; this appears to be within the required two business days (timely).

Context

• The 31,213-item grant is an RSU award (not an immediate open-market purchase); RSUs convert to actual shares only as they vest. Footnote F1 describes a multi-year (1/4 each year) vesting schedule; footnote F3 notes the sales were mandatory tax withholding tied to vesting of a prior award (with a similar 1/4-per-year schedule starting June 10, 2025).
• Sales for tax withholding are common and typically reflect tax obligations on vested equity rather than a directional investment decision.